April 29, 2024
“It’s been a difficult couple of years for BlackRock, the world’s biggest money manager. The firm is still enormously profitable, though it has recently taken some big hits because of its image as a promoter of progressive utopianism through its use of… Continue Reading…
January 10, 2024
“…The trade targets a surge in US 10-year yields to as high as 4.15% by Friday’s close of business, or a jump of about 0.15 percentage points from Thursday’s closing level. That would mark the biggest one-day rise in 10-year… Continue Reading…
March 25, 2021
“Oncolytics Biotech (ONCY)… Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that ONCY is a Strong Buy. Given its… Continue Reading…
January 6, 2021
“9 Meters Biopharma (NMTR)… Turning now to the rest of the Street, other analysts are on the same page. With 4 Buys and no Holds or Sells, the word on the Street is that NMTR is a Strong Buy. Given… Continue Reading…
December 23, 2020
“Palatin Technologies (PTN)… Overall, Palatin gets a Strong Buy rating from the analyst consensus, and that verdict is unanimous, based on 3 recent Buy reviews. The average price target, $2.17, implies an impressive 417% upside for the coming year… Mustang Bio… Continue Reading…
December 3, 2020
“Cinedigm Corporation (CIDM)… Currently, CIDM has 2 reviews on record, making the stock a Moderate Buy. The shares are selling for 53 cents, and the $2.75 average price target suggests an impressive 418% upside on the one-year time horizon… Kubient (KBNT)… To… Continue Reading…
November 13, 2020
“Sequans Communications (SQNS)… Sequans holds a unanimous Strong Buy rating from the analyst consensus, based on 4 Buy reviews given in the last two months. Furthermore, the average price target suggests it will more than double, growing by 148% from… Continue Reading…
October 20, 2020
“Neos Therapeutics (NEOS)… Turning now to the rest of the Street, 3 Buys and no Holds or Sells have been published in the last three months. Therefore, NEOS has a Strong Buy consensus rating. At $8.33, the average price target… Continue Reading…
September 30, 2020
“Seelos Therapeutics (SEEL)… Turning now to the rest of the Street, 2 Buys and no Holds or Sells have been published in the last three months. Therefore, SEEL has a Moderate Buy consensus rating. With the average price target clocking… Continue Reading…
May 8, 2020
“A precipitous decline in car sales amid the deadly coronavirus outbreak has caught the attention of Capitol Hill, where some lawmakers are now urging Congress to authorize new aid for the auto industry. The heightened push on Capitol Hill comes as the… Continue Reading…
Recent Comments